<DOC>
	<DOCNO>NCT02186275</DOCNO>
	<brief_summary>The purpose study determine vitamin D adjuvant therapy improve outcome ( i.e . few relapse ) quality life , include level physical activity , child newly diagnose Crohn 's disease ( CD ) .</brief_summary>
	<brief_title>The Vitamin D Pediatric Crohn 's Disease</brief_title>
	<detailed_description>Crohn 's disease chronic inflammatory condition affect segment digestive tract mouth anus . This condition associate increase risk relapse throughout course disease . Nearly 25 % patient Crohn 's disease pediatric age range . Many epidemiological data favor increase incidence pediatric Crohn 's disease . Environmental factor could explain increased incidence . Among sunlight exposure vitamin D deficiency suggest many author . Recent study describe vary dos oral vitamin D supplementation alter serum level 25 hydroxyvitamin D ( 25 ( OH ) D ) , study specifically address question whether vitamin D supplementation alter rate relapse/complications and/or quality life child diagnose CD . Current treatment CD diagnosis effective around time diagnosis , short long term , therapy inefficient lead allergic intolerance reaction . Altogether rate relapse year diagnosis significant . Thus , different therapeutic approach must investigate aim lower burden disease . From November 2012 July 2013 , conduct open label pilot cohort study aim investigate bioavailability tolerance high dos vitamin D3 ( 3,000 IU 4,000 IU per day ) administer orally adjunct therapy 20 child newly diagnose pediatric CD ( http : //clinicaltrials.gov/ct2/show/NCT01692808 ) . Data laboratory study , observational research pilot trial take together suggest vitamin D great importance genesis progression CD . Vitamin D deficiency could true risk factor disease occurrence and/or relapse . The result pilot study demonstrate child active CD diagnosis , daily dose 4,000 IU vitamin D well tolerate quickly increase blood level 25OHD3 100 nmol/L 100 % child CD diagnosis . Moreover maintenance dosage 2,000 IU day require ( sufficient ) maintain target several month . Currently adequately power study pediatric CD population explore relationship vitamin D therapy diagnosis CD outcome . We propose randomize controlled trial ( RCT ) study efficacy high-dose oral vitamin D , adjunct therapy , child newly diagnose CD , reduce relapse rate improve patient ' quality life . Primary Efficacy End Point : The proportion patient least one relapse 52 week randomization . Secondary efficacy endpoint : Quality life score , Cumulative steroid dose , Time first relapse , Duration corticotherapy , Number relapse , Number hospitalization Safety Endpoint : incidence hypercalcemia ( define correct serum calcium level &gt; 2.65 mmol/L ) , incidence hypercalciuria ( defined urinary calcium creatinine molar ratio ≥1.50 ) , incidence supra-optimal level 25OHD3 define serum level ≥ 250 nmol/L , rate study discontinuation due hypercalcemia hypercalciuria . Efficacy Variable : Occurrence relapse , Time relapse , Change QoL score baseline 26 week , 52 week . Change physical activity score baseline 26 week , 52 week .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>Eligibility Criteria : Diagnosis CD usual clinical , endoscopic histological criterion classify accord Paris classification Age randomization 9 18 year inclusively Interval diagnosis randomization 2 week 6 month diagnosis Pediatric Crohn 's Disease Activity Index ( PCDAI ) ≤ 30 inclusion Concurrent treatment corticosteroid and/or enteral nutrition and/or thiopurines ( azathioprine , 6mercaptopurine ) and/or methotrexate and/or 5aminosalicylic acid ( 5ASA ) and/or TNFα inhibitor ( Infliximab , Adalimumab ) . Patient diagnose severe complex perianal fistulizing CD ( define presence diagnosis high intersphincteric , transsphincteric , extrasphincteric , suprasphincteric complex perianal fistula ) Known chronic liver cholestasis ( define elevation conjugate bilirubin and/or gamma glutamyl transferase &gt; 3 upper limit normal ) Known renal dysfunction require chronic dialysis creatinine ≥ 100 micromol/L . Known congenital bone disease Known cystic fibrosis exocrine pancreatic insufficiency . Currently treat anticonvulsant metabolize cytochrome P450 Unable take oral capsule form .</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Crohn</keyword>
	<keyword>vitamin D</keyword>
	<keyword>remission</keyword>
	<keyword>inflammation</keyword>
	<keyword>tolerance</keyword>
</DOC>